Strategic partnership with Lupin to selectively broaden our General Medicine portfolio in emerging markets
“We look forward to working with Merck [KGaA, Darmstadt, Germany] leveraging our established world-class formulation development, manufacturing, supply chain, and regulatory capabilities to produce a range of medications that meet local needs. This strategic partnership builds on the existing close collaboration between our two companies. We are delighted to enter into this alliance, which is an extension of our existing partnership into a much larger, multi-regional one.”
Vinod Dhawan, Group President, Asia Pacific, Africa, Middle East, & Latin America at Lupin
Lupin supports us in the implementation of our General Medicines portfolio expansion initiative in emerging markets, addressing the local needs for affordable high-quality medicines, with first product launches expected in 2016, and with a focus especially on cardiovascular and diabetes diseases.
Lupin will provide us with product dossiers and supply finished products. We as marketing authorization holder, will leverage our strong commercial and medical teams in emerging markets to provide affordable high-quality medicines to patients through this alliance.